Across TCGA pan-cancer cohorts, PSENEN Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PSENEN data layer compared with 22 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PSENEN Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PSENEN expression acts as an unfavorable survival marker.

OV and SKCM are the cancer types where PSENEN Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.262	0.541	.019	18	view →
SKCM	DFS	Median	IV	0.036	0.433	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: PSENEN tumor-vs-normal RNA expression · all PSENEN data types